Sign in

CIK 0000715446 · Non-accelerated filer<br>Smaller reporting company

Anixa Biosciences Inc

Sign in to watch
Ticker
ANIX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Oct 31
Incorporated
DE
Entity type
operating
EIN
112622630
Phone
408-708-9808
Business address
3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
Former names
ITUS Corp, COPYTELE INC
  1. CORRESP Other Correspondence Between Filers and SEC Staff
  2. UPLOAD Other SEC-generated Letter
  3. S-3 Offering Registration Statement
  4. 10-Q Report Quarterly Report
  5. 4 Open-market buy Director bought 10,000 shares at $3.08 ($30,800)
  6. 4 Open-market buy Chief Executive Officer bought 5,000 shares at $3.16 ($15,800)
  7. 4 Open-market buy Director bought 5,000 shares at $3.39 ($16,950)
  8. 4 Open-market buy Director bought 10,000 shares at $3.14 ($31,400)
  9. 4 Open-market buy Chief Executive Officer bought 5,000 shares at $3.15 ($15,750)
  10. SCHEDULE 13D/A Stake Beneficial Ownership Report
  11. 4 Open-market buy Chief Executive Officer bought 10,000 shares at $2.85 ($28,500)
  12. 10-Q Report Quarterly Report
  13. 8-K Event Shareholder vote results · Regulation FD disclosure
  14. 10-Q Report Quarterly Report
  15. DEF 14A Proxy Proxy Statement
  16. 4 Open-market buy Director bought 5,000 shares at $2.82 ($14,100)
  17. 4 Open-market buy Director bought 3,000 shares at an average $2.94 ($8,820)
  18. 4 Open-market buy Director bought 2,000 shares at $3.01 ($6,020)
  19. 4 Open-market buy Director bought 6,000 shares at $2.59 ($15,540)
  20. 4 Open-market buy Director bought 10,000 shares at $2.57 ($25,700)

Page 3 of 50 · 983 filings